SecBot SecBot
3 ·Filed Nov 12, 2026

MTRI

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed4d 11h ago SEC0001193125-26-458265
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Monitor future Form 4 filings for insider transactions and the company's next quarterly report for post-merger financials. The option grant is standard for a new CEO and does not signal any near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$18.60
T+0 close · Nov 12, 2026 · via day close
Latest settled
+6.83%
T+1 · $19.87
Vs SPY
+8.74%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $18.60entry
  2. T+1 · 20h ago +6.83%α +8.74% · $19.87
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gregory Divis filed a Form 3 initial statement of beneficial ownership after becoming President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.) following a merger. The filing discloses options to purchase 1,454,398 shares at $10.37, vesting over three years. This is a routine Section 16 filing with no material price impact.

Key Facts

  • Gregory Divis appointed President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.)
  • Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a)
  • Divis holds stock options to buy 1,454,398 shares at $10.36 per share
  • Options vest 25% on July 20, 2027 and monthly thereafter through July 20, 2030
  • Filing relates to a merger effective November 6, 2026 involving Indigo Merger Sub Corp. and Pre-Merger Mentari

Financial Impact

No cash transaction; options valued at $10.36 strike price per share, vesting over ~3.7 years

dilution

Risk Factors

  • No financial data in filing to assess company performance
  • Merger integration risks not addressed in this filing

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-458265
Document: 0001193125-26-458265-index-headers.html0001193125-26-458265
Document: 0001193125-26-458265-index.html0001193125-26-458265
Document: 0001193125-26-458265.txt0001193125-26-458265

US Market Status

Market Closed · Opens in 6h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026